Prognosis
Pfizer Covid Pill Stops Hospitalization, Not Milder Symptoms
- Mixed results found in big study of pill in vaccinated people
- Separate trial confirms strong efficacy in the unvaccinated
This article is for subscribers only.
New study data showed Pfizer Inc.’s experimental Covid-19 pill was highly effective at keeping patients out of the hospital, but less adept at erasing milder symptoms often associated with breakthrough infections.
Pfizer disclosed findings from two studies in a statement Tuesday. In one, its treatment, Paxlovid, failed to meet the primary goal of reducing self-reported symptoms in 673 adults at standard risk of developing Covid-19 complications. The drug showed a trend toward reducing hospitalizations in the group by 70%, however.